Platelet News and Research

RSS

Emergency clopidogrel could save thousands of lives worldwide

Adding the anti-platelet drug clopidogrel to aspirin for the emergency treatment of heart attacks could save thousands of lives a year worldwide and prevent thousands of repeat heart attacks and strokes, according to new research presented at the American College of Cardiology annual conference.

9 Mar 2005

Substances in the urine of pregnant women could serve as a screening/diagnostic tool for preeclampsia

Researchers at Yale School of Medicine have found that specific substances in the urine of pregnant women could serve as a screening/diagnostic tool for preeclampsia (hypertension and proteinuria during pregnancy).

7 Mar 2005

Use of cilostazol, clopidogrel and aspirin results in a significant reduction of thrombotic complications in the prevention of heart attacks

Three drugs, each of which works in a different way, are used in anti-platelet therapy to help prevent restenosis (the reclogging of blood vessels after they have been cleared with percutaneous coronary intervention or PCI) or thrombosis (obstruction of an artery or vein by a blood clot).

7 Mar 2005

Stent trial fails to meet endpoints

Angiotech Pharmaceuticals has announced that results from the REALITY Trial, a head-to-head trial sponsored by Cordis Corporation, comparing the JNJ CYPHER® stent and the TAXUS® stent, were presented at the American College of Cardiology Annual Scientific Session. The trial failed to meet its primary endpoint.

7 Mar 2005

Studies find Aspirin resistance in up to 27% of Aspirin users

While aspirin remains a crucial and cost-effective therapy for the prevention and management of cardiovascular diseases, research suggests that a significant percentage of the 25 million Americans on a chronic aspirin regimen are "aspirin resistant," or do not achieve sufficient antiplatelet effects from aspirin.

7 Mar 2005

St. John's wort increases effectiveness of Plavix

The widely used herbal remedy St. John's wort appears to amplify the action of the popular blood-thinning drug clopidogrel, sold as Plavix, a small new clinical study finds.

6 Mar 2005

Growing evidence base supports focus on mind-body connection in heart disease

Cardiologists should recognize and help manage depression, stress and other common psychosocial risk factors that play a powerful role in the wellbeing and health outcomes of heart disease patients, according to an article(PDF) in the March 1, 2005 issue of the Journal of the American College of Cardiology.

1 Mar 2005

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver, according to a recent study that compared the effects of celecoxib, naproxen, and a placebo on cirrhotic patients in a double-blind randomized controlled study.

22 Feb 2005

Blood tests improve within two weeks of quitting smoking

Long-term smokers who quit may benefit from almost immediate improvements in blood platelet function, which could potentially reduce their risk of heart attacks or strokes caused by blood clots, according to a new study in the Feb. 15, 2005 issue of the Journal of the American College of Cardiology.

16 Feb 2005

Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers

Physicians are challenged in treating heart patients who may be at high-risk for gastrointestinal bleeding from aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Factors that place patients at high-risk include a history of ulcers or gastrointestinal complications such as bleeding, increased age and congestive heart failure.

20 Jan 2005

Clopidogrel (Plavix®) responses appear normal in largest data set

Although individual patients respond differently to treatment with the anti-platelet medication clopidogrel (brand name Plavix®), those variations appear normal and may not indicate important differences in the effectiveness of treatment, according to a new study (PDF file) in the Jan. 18, 2005 issue of the Journal of the American College of Cardiology.

19 Jan 2005

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.

17 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

First assessment tool to evaluate Quebec Platelet Disorder (QPD)

Researchers at McMaster University have developed the first assessment tool of its kind for evaluating risks faced by Canadians suffering from a rare and often fatal bleeding disorder.

22 Dec 2004

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

A new treatment for an incurable blood disorder proves a worse option for patients' health than an older treatment, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Platelet News and Research

Emergency clopidogrel could save thousands of lives worldwide

Substances in the urine of pregnant women could serve as a screening/diagnostic tool for preeclampsia

Use of cilostazol, clopidogrel and aspirin results in a significant reduction of thrombotic complications in the prevention of heart attacks

Stent trial fails to meet endpoints

Studies find Aspirin resistance in up to 27% of Aspirin users

St. John's wort increases effectiveness of Plavix

Growing evidence base supports focus on mind-body connection in heart disease

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver

Blood tests improve within two weeks of quitting smoking

Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers

Clopidogrel (Plavix®) responses appear normal in largest data set

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Potential new therapies for cancer and bleeding disorders

First assessment tool to evaluate Quebec Platelet Disorder (QPD)

New insight into anticoagulation therapies

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News